Reata’s pivotal data in Friedreich ataxia point to submissions

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data.

Reata Pharmaceuticals Inc. (NASDAQ:RETA) announced after market close Monday that omaveloxolone met the primary endpoint in Part 2 of the Phase II MOXIe trial. Omaveloxolone improved modified Friedreich’s Ataxia Rating Scale (mFARS) scores after 48 weeks vs. placebo (-1.55 points vs. +0.85 points, p=0.014) in patients with the neuromuscular disorder...